These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 24256258)

  • 41. Potential Therapeutical Contributions of the Endocannabinoid System towards Aging and Alzheimer's Disease.
    Bonnet AE; Marchalant Y
    Aging Dis; 2015 Sep; 6(5):400-5. PubMed ID: 26425394
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Emerging Promise of Cannabinoids for the Management of Pain and Associated Neuropathological Alterations in Alzheimer's Disease.
    Uddin MS; Mamun AA; Sumsuzzman DM; Ashraf GM; Perveen A; Bungau SG; Mousa SA; El-Seedi HR; Bin-Jumah MN; Abdel-Daim MM
    Front Pharmacol; 2020; 11():1097. PubMed ID: 32792944
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Role of neuroinflammation in adult neurogenesis and Alzheimer disease: therapeutic approaches.
    Fuster-Matanzo A; Llorens-Martín M; Hernández F; Avila J
    Mediators Inflamm; 2013; 2013():260925. PubMed ID: 23690659
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Endocannabinoid metabolism and Alzheimer's disease.
    Chen C
    Neural Regen Res; 2022 Sep; 17(9):1987-1988. PubMed ID: 35142686
    [No Abstract]   [Full Text] [Related]  

  • 45. The multifaceted potential of the lipid transmitter oleoylethanolamide to treat alcohol-induced neuroinflammation and alcohol use disorders.
    Orio L
    Neural Regen Res; 2020 Jan; 15(1):71-72. PubMed ID: 31535652
    [No Abstract]   [Full Text] [Related]  

  • 46. Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer's Disease.
    Liu CS; Chau SA; Ruthirakuhan M; Lanctôt KL; Herrmann N
    CNS Drugs; 2015 Aug; 29(8):615-23. PubMed ID: 26271310
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The role of endocannabinoid signaling in the molecular mechanisms of neurodegeneration in Alzheimer's disease.
    Bedse G; Romano A; Lavecchia AM; Cassano T; Gaetani S
    J Alzheimers Dis; 2015; 43(4):1115-36. PubMed ID: 25147120
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The potential therapeutic effects of THC on Alzheimer's disease.
    Cao C; Li Y; Liu H; Bai G; Mayl J; Lin X; Sutherland K; Nabar N; Cai J
    J Alzheimers Dis; 2014; 42(3):973-84. PubMed ID: 25024327
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cannabinoids for treatment of Alzheimer's disease: moving toward the clinic.
    Aso E; Ferrer I
    Front Pharmacol; 2014; 5():37. PubMed ID: 24634659
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia: An-Open Label, Add-On, Pilot Study.
    Shelef A; Barak Y; Berger U; Paleacu D; Tadger S; Plopsky I; Baruch Y
    J Alzheimers Dis; 2016; 51(1):15-9. PubMed ID: 26757043
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neurological Aspects of Medical Use of Cannabidiol.
    Mannucci C; Navarra M; Calapai F; Spagnolo EV; Busardò FP; Cas RD; Ippolito FM; Calapai G
    CNS Neurol Disord Drug Targets; 2017; 16(5):541-553. PubMed ID: 28412918
    [TBL] [Abstract][Full Text] [Related]  

  • 52.
    Watt G; Karl T
    Front Pharmacol; 2017; 8():20. PubMed ID: 28217094
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cannabidiol promotes amyloid precursor protein ubiquitination and reduction of beta amyloid expression in SHSY5YAPP+ cells through PPARγ involvement.
    Scuderi C; Steardo L; Esposito G
    Phytother Res; 2014 Jul; 28(7):1007-13. PubMed ID: 24288245
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Endocannabinoids and Neurodegenerative Disorders: Parkinson's Disease, Huntington's Chorea, Alzheimer's Disease, and Others.
    Fernández-Ruiz J; Romero J; Ramos JA
    Handb Exp Pharmacol; 2015; 231():233-59. PubMed ID: 26408163
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Involvement of the endocannabinoid system in osteoarthritis pain.
    La Porta C; Bura SA; Negrete R; Maldonado R
    Eur J Neurosci; 2014 Feb; 39(3):485-500. PubMed ID: 24494687
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Reductions in endocannabinoid levels and enhanced coupling of cannabinoid receptors in the striatum are accompanied by cognitive impairments in the AβPPswe/PS1ΔE9 mouse model of Alzheimer's disease.
    Maroof N; Ravipati S; Pardon MC; Barrett DA; Kendall DA
    J Alzheimers Dis; 2014; 42(1):227-45. PubMed ID: 24844690
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa.
    de Mello Schier AR; de Oliveira Ribeiro NP; Coutinho DS; Machado S; Arias-Carrión O; Crippa JA; Zuardi AW; Nardi AE; Silva AC
    CNS Neurol Disord Drug Targets; 2014; 13(6):953-60. PubMed ID: 24923339
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Natural Phytochemicals in the Treatment and Prevention of Dementia: An Overview.
    Libro R; Giacoppo S; Soundara Rajan T; Bramanti P; Mazzon E
    Molecules; 2016 Apr; 21(4):518. PubMed ID: 27110749
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Delineating the Efficacy of a Cannabis-Based Medicine at Advanced Stages of Dementia in a Murine Model.
    Aso E; Andrés-Benito P; Ferrer I
    J Alzheimers Dis; 2016 Oct; 54(3):903-912. PubMed ID: 27567873
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cannabis-based medicine reduces multiple pathological processes in AβPP/PS1 mice.
    Aso E; Sánchez-Pla A; Vegas-Lozano E; Maldonado R; Ferrer I
    J Alzheimers Dis; 2015; 43(3):977-91. PubMed ID: 25125475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.